基本信息
浏览量:28
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Since 2016 I lead my own lines of research, and since 2018 I am Senior Investigator with my own research group and independent funding. I am interested in the study of novel alternative uses for live vaccines in diseases different from tuberculosis, including cancer and allergies. I have supervised 3 doctoral theses and 4 more are ongoing. I have directed several end-degree and end-master students. Since 2007, I have published 68
scientific contributions (24 as first, last or corresponding author), including 60 original
manuscripts, 7 reviews and 1 book chapter (2062 cites and h-index 28). In 2009, I received the Extraordinary Doctorate Prize. In 2016, I was awarded with the Early Career Scientist Recognition given by CTVD (Collaboration for TB Vaccine Discovery), funded by Bill and Melinda Gates Foundation. In 2019, I received the “Rafael Gómez-Lus” award from the Royal Academy of Medicine of Zaragoza, for the best National publication in microbiology. I am co-inventor of 4 patents about "Tuberculosis Vaccines" owned by the University of Zaragoza (one of them shared at 50% with the company Biofabri). Two of them (presented in 2018 and 2019) are international and have been published in different countries worldwide, including Europe, USA, Canada, Brazil, China, Japan, India or Australia. My main contributions to science are:
1. Development of MTBVAC. Since 2009, I have actively participated in the different steps
to support MTBVAC development: from GMP vaccine preclinical characterization to clinical development. I coordinated the preclinical mouse experiments required by Swiss Authorities (SwissMedic) for the authorization of MTBVAC to enter into first-in-human trial (Spertini et al, 2015, Lancet Resp Med). I was involved in the clinical protocol preparation of the phase Ib,
performed in South Africa in neonates (Tameris et al, 2019, Lancet Resp Med), as well as the phase IIa in adults and neonates, which recently finished. At present, I am also involved in the preparation of the phase III efficacy trial, expected to start in 2022. Remarkably, the results derived from my manuscript published in Nature Communications in 2017 (as senior author) represent the basis to design an assay to differentiate MTBVAC-vaccinated and tuberculosisinfected individuals, which is being tested at present in the clinical trials.
2. Respiratory delivery of live tuberculosis vaccines. This research aims to improve tuberculosis vaccine efficacy by changing the route of administration, from intradermal (used in clinic), to respiratory, with the intention to stimulate immunity in the target organ of tuberculosis. I started this line of research during my post-doctoral stage, and I continue it as independent researcher. I have published three manuscripts about this topic as main author in Clinical Vaccine Immunology (2013), Journal of Infectious Disease (2016), and the last one in Science Immunology in 2021, where we demonstrated for the first time the acquisition of immunological memory by alveolar macrophages. These results were orally presented in the last Global Forum on TB vaccines, in Toulouse (Feb 2022), one of the major events in the TB vaccine field. Together with other International groups, I recently obtained an European Project to extend this line of research, where I am Principal Investigator at University of Zaragoza. In addition, we also demonstrated that respiratory vaccine administration could be a promising therapy to treat allergic asthma (Tarancon et al, 2020). Altogether, respiratory MTBVAC administration for treatment of asthma or tuberculosis was protected by an international patent in 2019.
3. Use of live tuberculosis vaccines as cancer therapy. This line of research started
in 2016, during the thesis of Samuel Álvarez, who optimized the methodology to implement orthotopically bladder tumors in mice, and who firstly demonstrated the higher antitumoral efficacy of intravesical MTBVAC compared to BCG (Alvarez-Arguedas et al, Translational Medicine, 2018). In 2022 I published another manuscript as corresponding author describing key events in the antitumoral mechanism of MTBVAC (Moreo et al, Journal of Immunotherapy for Cancer, 2022). Thanks to these studies, we recently got the commitment of the MTBVAC manufacturer Biofabri to advance MTBVAC clinical evaluation for bladder cancer, a project that we, Biofabri and our group, are starting to move at present. Since 2018, I have obtained uninterrupted funding as principal investigator to develop this line of research, including European National, Regional and private funding (AECC) grants.
研究兴趣
论文共 66 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2024)
Marco Polo Peralta Alvarez, Holly Jones, Hugo Redondo Azema, Chloe Davis,Andrew D White,Charlotte Sarfas,Mike Dennis,Shuailin Li,Daniel Wright,Eugenia Puentes,Simon Kimuda,Sandra Belij-Rammerstorfer,
Frontiers in immunology (2024): 1387454-1387454
Luna Minute,Marta Bergon-Gutierrez,Pablo Mata-Martinez, Jaime Fernandez-Pascual,Veronica Terron, Laura Bravo-Robles, Gulce Bicakcioglu, Gabriela Zapata-Fernandez,Nacho Aguilo,Eduardo Lopez-Collazo,Carlos del Fresno
Scientific reportsno. 1 (2024): 13133-13133
Research Square (Research Square) (2023)
Eduardo Moreo, Aitor Jarit-Cabanillas,Iñaki Robles-Vera,Santiago Uranga,Claudia Guerrero,Ana Belén Gómez,Pablo Mata-Martínez,Luna Minute, Miguel Araujo-Voces,María José Felgueres,Gloria Esteso,Iratxe Uranga-Murillo,
Nature communicationsno. 1 (2023): 6090-17
Regular and Young Investigator Award Abstracts (2022): A1114-A1114
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn